Posters
« Back
New BIONET Compounds for CNS Diseases
EP28699
Poster Title: New BIONET Compounds for CNS Diseases
Submitted on 14 Jun 2018
Author(s): Steve Brough1, Andrew Lowerson1 and Nikolay T. Tzvetkov2
Affiliations: 1. Key Organics Ltd, Highfield Road Industrial Estate, Camelford, Cornwall, PL32 9RA, UK 2. NTZ Lab Ltd., Krasno selo 198, 1618 Sofia, Bulgaria
Poster Views: 586
View poster »


Poster Information
Abstract: A new collection of nine CNS active compounds, which have been recently licensed, is now available in the BIONET collection. This screening collection with experimentally-determined bioactivity, lipophilicity (LogP/D7.4), aqueous solubility, GIT and BBB permeability, chemical stability and toxicity will address the need of new, robust, and multipotent small molecules for the treatment and diagnosis of CNS diseases, such as Parkinson´s disease, Alzheimer´s disease, dementia and/or other neurodegenerative diseases [1–3]. NMR and LC-MS analysis allowed the careful control of the compound quality. Importantly, the newly discovered and well-validated molecules are enriched in heterocyclic scaffolds and specifically substituted phenyl moieties commonly found in CNS drug candidates, and spans chemical space that minimally overlaps with existing commercial collections. In addition, the compounds are easily accessible and offer the possibility of broad structural diversities in order to further explore the chemical space within further biological screening on relevant CNS targets [4]. This poster will summarize the design, synthesis, biological activity, and experimental ADME features of this potential next generation compounds that are available for further screening and elaboration for CNS disease treatment.Summary: A new BIONET CNS Compound collection is available for further development and screening on relevant CNS targets. All compounds in the new collection have been analyzed by 1H NMR and LC/MS for structure verification and purity. Additionally, all compounds are experimentally tested for their ability to cross GIT and BBB, and furthermore, identified as promising drug and radioligand candidates, including diagnostics for positron emission tomography (PET).References: 1. Tzvetkov, N. T. PCT Patent WO 2014/107771 A1, NTZ Lab Ltd., 2014.
2. Tzvetkov, N. T.; Stammler, H.-G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar,
selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur. J. Med. Chem., 2017, 127, 470–492.
3. Tzvetkov, N. T.; Hinz, S.; Küppers, P.; Gastreich, M.; Müller, C. E. Indazole- and indole-5-carboxamides: Selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. J. Med. Chem., 2014, 57, 6679–6703.
4. Tzvetkov, N. T. and Antonov, L. Subnanomolar indazole-5-carboxamides inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimized solubility and brain penetration.
J. Enz. Inh. Med. Chem., 2017, 32(1), 960–967.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


2D FT0ICR MS/MS analysis of IgG1
Johanna Paris 1 , Tomos E. Morgan 1 , Yuko P. Y. Lam 1 Christopher A. Wootton 1 Mark André Delsuc 2 , Mark P. Barrow 1 , John O’Hara 3 , and Peter B. O’Connor 1

Primary Human Hepatocytes 3D in vitro Culture Model for Studying Hepatic Function
Sujoy Lahiri, Julia Tritapoe, Kate Comstock, Michael F. Millett, Mark Kennedy, Theresa V. Nguyen, Deborah K. Tieberg, David T. Kuninger

FINGERPRINT 1H- NMR BASED ON THE CHEMICAL PROFILING OF COLOMBIAN RED PROPOLIS
Guillermo Salamanca Grosso; Monica Patricia Osorio Tangarife; David Garcia Mendez; Julien Wist

High speed untargeted 4D-lipidomics LC-MS/MS workflows with Parallel Accumulation Serial Fragmentation (PASEF)
Ulrike Schweiger-Hufnagel1, Aiko Barsch1, Sven W. Meyer1

TMT Quantification for Shotgun Proteomics on a Trapped-Ion-Mobility quadrupole-Time-Of- Flight mass spectrometer (TIMS-QTOF) powered by Parallel-Accumulation and Serial- Fragmentation (PASEF)
Matt Willetts1, Shourjo Ghose1 Heiner Koch2, Scarlet Koch2, Markus Lubeck2, Gary Kruppa1